Thomas Powles MBBS, MRCP, MD, discusses the changes to the frontline landscape of bladder cancer and where research should focus moving forward.
Most pediatric patients with immune thrombocytopenia had rapid and durable platelet responses when treated with the thrombopoietin fusion protein analog romiplostim.
Nonpediatric young adults with stage III/IV Hodgkin lymphoma had significantly better progression-free survival when treated with brentuximab vedotin and conventional chemotherapy compared with standard therapy.
Historically, the management of localized prostate cancer has centered on removal or ablation of the entire gland with either extirpative surgery or radiation. However, the subsequent unacceptable adverse events profile can be devastating and life altering for many patients.
Robert Andtbacka, MD, discusses the current use of talimogene laherparepvec in melanoma and future directions with this type of treatment.
Adding the BTK inhibitor acalabrutinib to bendamustine and rituximab induced high overall response rates in both treatment-naive and relapsed/refractory patients with mantle cell lymphoma.
Nivolumab demonstrated durable response and overall survival rates in a real-world analysis of patients with platinum-refractory, recurrent/metastatic head and neck squamous cell carcinoma.
A growing understanding about the underlying biology of myelofibrosis has helped improve the diagnosis and treatment of the disease during the past decade and is paving the way for further advancements.
Stephen L. Graziano, MD, discusses available and emerging targeted therapies for common driver mutations in patients with non–small cell lung cancer and the sequencing strategies beyond frontline treatment.
An investigational antibody directed against Dickkopf-3 may be the key in suppressing tumor growth and extending survival in patients with pancreatic adenocarcinoma.